Indomethacin Prevents Post-ERCP Pancreatitis in Low-Risk Patients

A real-world analysis supports routine post–endoscopic retrograde cholangiopancreatography administration of rectal indomethacin.

Rectal indomethacin has shown clear benefit in preventing post–endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), but studies have been limited to those at high risk for PEP.

To assess the efficacy of rectal indomethacin in preventing PEP in lower-risk patients, researchers conducted a retrospective cohort study involving 4017 patients undergoing ERCP during a 7-year period at a single expert ERCP center.

Postprocedure rectal indomethacin use (occurring only in the second half of the study) was significantly associated with a 65% reduced risk for PEP and an 83% reduced risk for moderate-to-severe PEP. This dramatic effectiveness of rectal indomethacin was also seen in those with malignant biliary obstruction (823 patien…

Reviewing Author

M. Brian Fennerty, MD

Disclosures

Consultant/Advisory boardDSMB for Intec trial; SERES trial; C3 Therapeutics trial

M. Brian Fennerty, MD

Disclosures

Consultant/Advisory boardDSMB for Intec trial; SERES trial; C3 Therapeutics trial

Indomethacin Prevents Post-ERCP Pancreatitis in Low-Risk Patients

Topics

Reviewing Author